Small Molecules for Precision Medicine

Learn More about Arqule

We are pursuing multiple programs in biomarker-defined oncology and rare disease indications

Targeted Approach to Cancer

Clinical Trials

Research & Development

Product Pipeline

Targeted Approach To

Rare Diseases

News & Events

September 29, 2017

Proteus Syndrome Phase 1 Data Presentation

November 29, 2018

ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

December 3, 2018

ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting

More News & Events »